NCT06995508View on ClinicalTrials.gov

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

November 15, 2030

Study Completion Date

November 15, 2031

Conditions

Cancer-Associated AnorexiaHead and Neck Squamous Cell CarcinomaNeck Squamous Cell Carcinoma of Unknown Primary

Interventions

OTHER

Best Practice

Given standard of care symptom management

DRUG

Olanzapine

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors

lead

Roswell Park Cancer Institute

OTHER

NCT06995508 - Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial | Biotech Hunter | Biotech Hunter